Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FBP1 | P09467 | 15/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4137617 | 0.82 | FBP1 (1.00) | FBP1ALDH1A1CYP1A2 | |
| SCHEMBL4129692 | 0.81 | FBP1 (1.00) | FBP1ALDH1A1CYP1A2 | |
| SCHEMBL4129844 | 0.80 | FBP1 (1.00) | FBP1ALDH1A1CYP1A2 | |
| SCHEMBL4121755 | 0.77 | FBP1 (1.00) | FBP1ALDH1A1CYP1A2 | |
| SCHEMBL4134495 | 0.76 | FBP1 (1.00) | FBP1ALDH1A1CYP1A2 | |
| SCHEMBL4129141 | 0.72 | FBP1 (0.62) | FBP1ALDH1A1CYP1A2 | |
| SCHEMBL4146195 | 0.67 | FBP1 (0.67) | FBP1ALDH1A1CYP1A2 | |
| SCHEMBL4123699 | 0.65 | FBP1 (1.00) | FBP1ALDH1A1 | |
| SCHEMBL4135529 | 0.65 | FBP1 (0.80) | FBP1ALDH1A1CYP1A2 | |
| SCHEMBL18974157 | 0.64 | FBP1 (0.71) | FBP1ALDH1A1CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7491829-B2 | RAF inhibitor compounds and methods | ARRAY BIOPHARMA INC. (US) | 2009-02-17 | — | — | US | claimed |
| US-20060189627-A1 | RAF inhibitor compounds and methods | ARRAY BIOPHARMA INC. | 2006-08-24 | — | — | US | claimed |
| US-20090192121-A1 | NOVEL BISAMIDATE PHOSPHONATE PRODRUGS | JIANG TAO | 2009-07-30 | — | — | US | disclosed |
| US-20090176809-A1 | RAF INHIBITOR COMPOUNDS AND METHODS | LAIRD ELLEN | 2009-07-09 | — | — | US | disclosed |
| US-7491829-B2 | RAF inhibitor compounds and methods | ARRAY BIOPHARMA INC. (US) | 2009-02-17 | — | — | US | disclosed |
| US-20080015195-A1 | Novel Heteroaromatic Inhibitors of Fructose-1,6-Bisphosphatase | METABASIS THERAPEUTICS, INC. (US) | 2008-01-17 | — | — | US | disclosed |
| US-20080004226-A1 | Combination of FBPase Inhibitors and Insulin Sensitizers for the Treatment of Diabetes | METABASIS THERAPEUTICS, INC. (US) | 2008-01-03 | — | — | US | disclosed |
| US-7312219-B2 | Heteroaromatic inhibitors of fructose 1,6-bisphosphatase | METABASIS THERAPEUTICS, INC. (US) | 2007-12-25 | — | — | US | disclosed |
| US-20070232571-A1 | Novel Heteroaromatic Inhibitors of Fructose-1,6-Bisphosphatase | METABASIS THERAPEUTICS, INC. (US) | 2007-10-04 | — | — | US | disclosed |
| US-20060189627-A1 | RAF inhibitor compounds and methods | ARRAY BIOPHARMA INC. | 2006-08-24 | — | — | US | disclosed |
| US-6965033-B2 | Bisamidate phosphonate prodrugs | METABASIS THERAPEUTICS, INC. (US) | 2005-11-15 | — | — | US | disclosed |
| EP-1112275-B9 | NOVEL HETEROAROMATIC INHIBITORS OF FRUCTOSE 1,6-BISPHOSPHATASE | METABASIS THERAPEUTICS INC (US) | 2004-03-10 | — | — | EP | disclosed |
| EP-1112275-B1 | NOVEL HETEROAROMATIC INHIBITORS OF FRUCTOSE 1,6-BISPHOSPHATASE | METABASIS THERAPEUTICS INC (US) | 2003-07-30 | — | — | EP | disclosed |
| US-6489476-B1 | FRUCTOSE-1,6-BISPHOSPHATASE ENZYME INHIBITORS ARE USEFUL IN THE TREATMENT OF DIABETES AND OTHER CONDITIONS ASSOCIATED WITH ELEVATED BLOOD GLUCOSE OR EXCESS GLYCOGEN STORAGE. | METABASIS THERAPEUTICS, INC. | 2002-12-03 | — | — | US | disclosed |
| US-20020173490-A1 | Novel bisamidate phosphonate prodrugs | METABASIS THERAPEUTICS, INC. | 2002-11-21 | — | — | US | disclosed |
| EP-1143955-A3 | A COMBINATION OF FBPase INHIBITORS AND INSULIN SENSITIZERS FOR THE TREATMENT OF DIABETES | Metabasis Therapeutics Inc. (US) | 2002-08-28 | — | — | EP | disclosed |
| EP-1143955-A2 | A COMBINATION OF FBPase INHIBITORS AND INSULIN SENSITIZERS FOR THE TREATMENT OF DIABETES | Metabasis Therapeutics Inc. (US) | 2001-10-17 | — | — | EP | disclosed |
| EP-1112275-A1 | NOVEL HETEROAROMATIC INHIBITORS OF FRUCTOSE 1,6-BISPHOSPHATASE | Metabasis Therapeutics, Inc. (US) | 2001-07-04 | — | — | EP | disclosed |
| WO-2000038666-A2 | A COMBINATION OF FBPase INHIBITORS AND INSULIN SENSITIZERS FOR THE TREATMENT OF DIABETES | METABASIS THERAPEUTICS, INC. (US) | 2000-07-06 | — | — | WO | disclosed |
| WO-2000014095-A1 | NOVEL HETEROAROMATIC INHIBITORS OF FRUCTOSE 1,6-BISPHOSPHATASE | METABASIS THERAPEUTICS, INC. (US) | 2000-03-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080015195-A1 | Novel Heteroaromatic Inhibitors of Fructose-1,6-Bisphosphatase | FBP1, ALDOA, G6PC1 | FBP1 1/4885ALDH1A1 640/4885CYP1A2 731/4885 |
| US-20020173490-A1 | Novel bisamidate phosphonate prodrugs | FBP1, PFKFB1, G6PC1 | FBP1 1/4885ALDH1A1 852/4885CYP1A2 2039/4885 |
| US-20060189627-A1 | RAF inhibitor compounds and methods | BRAF, RAF1, ARAF | FBP1 462/4885ALDH1A1 1320/4885CYP1A2 3511/4885 |
| US-20090192121-A1 | NOVEL BISAMIDATE PHOSPHONATE PRODRUGS | FBP1, PFKFB1, PFKFB2 | FBP1 1/4885ALDH1A1 1609/4885CYP1A2 2357/4885 |
| US-20090176809-A1 | RAF INHIBITOR COMPOUNDS AND METHODS | BRAF, RAF1, ARAF | FBP1 462/4885ALDH1A1 1320/4885CYP1A2 3511/4885 |
| US-20070232571-A1 | Novel Heteroaromatic Inhibitors of Fructose-1,6-Bisphosphatase | FBP1, ALDOA, G6PC1 | FBP1 1/4885ALDH1A1 640/4885CYP1A2 731/4885 |
| US-20080004226-A1 | Combination of FBPase Inhibitors and Insulin Sensitizers for the Treatment of Diabetes | FBP1, G6PC1, IRS1 | FBP1 1/4885ALDH1A1 3879/4885CYP1A2 4368/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.